PL2133091T3 - Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy - Google Patents

Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy

Info

Publication number
PL2133091T3
PL2133091T3 PL09155775T PL09155775T PL2133091T3 PL 2133091 T3 PL2133091 T3 PL 2133091T3 PL 09155775 T PL09155775 T PL 09155775T PL 09155775 T PL09155775 T PL 09155775T PL 2133091 T3 PL2133091 T3 PL 2133091T3
Authority
PL
Poland
Prior art keywords
diabetes
compositions
treatment
supramolecular insulin
assemblies useful
Prior art date
Application number
PL09155775T
Other languages
English (en)
Inventor
Avadhesha Suriola
Sarika Gupta
Mahendra Pal Singh
Tandrika Chattopadhyay
Original Assignee
Nat Institute Of Immunology
Indian Inst Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Institute Of Immunology, Indian Inst Scient filed Critical Nat Institute Of Immunology
Publication of PL2133091T3 publication Critical patent/PL2133091T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09155775T 2008-04-07 2009-03-20 Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy PL2133091T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN914DE2008 2008-04-07
EP09155775.1A EP2133091B1 (en) 2008-04-07 2009-03-20 Compositions comprising supramolecular insulin assemblies useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
PL2133091T3 true PL2133091T3 (pl) 2014-03-31

Family

ID=40841040

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09155775T PL2133091T3 (pl) 2008-04-07 2009-03-20 Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy

Country Status (12)

Country Link
US (3) US20110034385A1 (pl)
EP (2) EP2282763B1 (pl)
JP (3) JP2011516541A (pl)
CN (1) CN102088997A (pl)
AU (2) AU2008354530B2 (pl)
CA (1) CA2720864C (pl)
ES (1) ES2425491T3 (pl)
HR (1) HRP20130772T1 (pl)
PL (1) PL2133091T3 (pl)
PT (1) PT2133091E (pl)
WO (1) WO2009125423A2 (pl)
ZA (2) ZA200902374B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2280020T3 (en) 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
DE102006033167A1 (de) * 2006-07-10 2008-01-24 Gelita Ag Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
AU2008316636B2 (en) * 2007-10-24 2014-02-06 Mannkind Corporation Delivery of active agents
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
AR072114A1 (es) 2008-06-13 2010-08-04 Mannkind Corp Un inhalador de polvo seco y sistema para suministro de farmacos
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012156811A2 (en) * 2011-05-19 2012-11-22 National Institute Of Immunology Compositions useful for the treatment of inflammatory disease or disorders
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
WO2013102921A2 (en) * 2011-11-17 2013-07-11 Sanzyme Limited Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
WO2014054046A1 (en) * 2012-10-04 2014-04-10 Gavish-Galilee Bio Applications Ltd Ordered reversible fibrils, aggregates and multimers of proteins and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CN104870009B (zh) 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106977609B (zh) * 2017-04-19 2020-07-28 刘崇东 一种融合蛋白、制备方法及其应用
CN111714643A (zh) * 2019-03-22 2020-09-29 约翰霍普金斯大学 一种单宁酸/Fe3+纳米颗粒体系、药物递送方法
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
AU2002248464A1 (en) * 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
ES2380437T3 (es) * 2003-06-03 2012-05-11 Novo Nordisk A/S Composiciones farmacéuticas de péptido GLP-1 estabilizadas
EP1638517A4 (en) * 2003-06-30 2010-01-06 Univ Tel Aviv Future Tech Dev PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF THESE DISEASES
US8173148B2 (en) * 2004-11-10 2012-05-08 Tolmar Therapeutics, Inc. Stabilized polymeric delivery system comprising a water-insoluble polymer and an organic liquid
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
WO2007047834A2 (en) * 2005-10-18 2007-04-26 Biocon Limited Oral peptide conjugates for metabolic diseases
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US8440214B2 (en) * 2006-01-31 2013-05-14 Boston Scientific Scimed, Inc. Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments
EP2120859B1 (en) * 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals

Also Published As

Publication number Publication date
CN102088997A (zh) 2011-06-08
ZA201007114B (en) 2011-06-29
US8940691B2 (en) 2015-01-27
PT2133091E (pt) 2013-08-28
US20090258818A1 (en) 2009-10-15
ZA200902374B (en) 2009-12-30
CA2720864C (en) 2017-07-04
EP2133091A3 (en) 2010-07-14
AU2009200906A1 (en) 2010-03-25
US20110034385A1 (en) 2011-02-10
ES2425491T3 (es) 2013-10-15
US20130217621A1 (en) 2013-08-22
CA2720864A1 (en) 2009-10-15
EP2133091B1 (en) 2013-05-22
AU2008354530B2 (en) 2014-02-27
JP5964373B2 (ja) 2016-08-03
EP2282763A2 (en) 2011-02-16
US8426362B2 (en) 2013-04-23
WO2009125423A2 (en) 2009-10-15
JP2011516541A (ja) 2011-05-26
EP2282763B1 (en) 2013-12-11
JP2014231520A (ja) 2014-12-11
HRP20130772T1 (hr) 2013-12-06
EP2133091A2 (en) 2009-12-16
JP5592077B2 (ja) 2014-09-17
JP2009249382A (ja) 2009-10-29
WO2009125423A3 (en) 2010-03-04
AU2008354530A1 (en) 2009-10-15
AU2009200906B2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
PL2133091T3 (pl) Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
HK1161275A1 (en) Halogen-stabilized insulin
GB0802403D0 (en) Compositions for the treatment of oxidative stress
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
HK1137149A1 (en) Pharmaceutical composition for treatment of diabetic complications
IL199829A0 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
IL206904A0 (en) Beta--amino acid derivatives for treatment of diabetes
ZA201009182B (en) Tetrahydrocinnolines as 11 beta hsd1 inhibitors for diabetes
EP2301543A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
GB0812019D0 (en) Insulin
IL211267A0 (en) Oxadiazole derivatives for the treatment of diabetes
EP2320879A4 (en) PHARMACEUTICAL COMPOSITION COMPRISES JASMONATES
EP2327406A4 (en) STABILIZED PHARMACEUTICAL COMPOSITION
IL209947A (en) Compounds for the treatment of corneal inflammation
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
EP2285818A4 (en) BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS
HK1147700A1 (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including man
EP2352541A4 (en) CATHETER LOCK COMPOSITION
EP2356986A4 (en) COMPOSITION FOR METABOLIC SYNDROME TREATMENT
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych